Exploring Aligos Therapeutics, Inc. (ALGS) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Aligos Therapeutics, Inc. (ALGS) and wondering who's investing in this clinical-stage biopharmaceutical company? As of December 31, 2024, a total of 52 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a combined 1,640,579 shares. Curious about the major players? Let's delve into the details of who the big shareholders are and what's driving their investment decisions, especially considering the company's $131.21 million in losses for 2024 and a stock price decline of 77.39% from April 16, 2024, to April 15, 2025.

Aligos Therapeutics, Inc. (ALGS) Who Invests in Aligos Therapeutics, Inc. (ALGS) and Why?

Understanding the investor profile of Aligos Therapeutics, Inc. (ALGS) involves examining the diverse range of entities and individuals who hold shares in the company, as well as their motivations and strategies.

Key Investor Types:

The investor base of Aligos Therapeutics, Inc. (ALGS) can be categorized into several key types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions are often based on personal research, recommendations from financial advisors, or general market sentiment.
• Institutional Investors: This category includes entities that invest on behalf of others, such as mutual funds, pension funds, insurance companies, and university endowments. Institutional investors typically have larger positions and conduct extensive due diligence before investing.
• Hedge Funds: These are investment partnerships that use pooled funds and employ various strategies to generate returns. Hedge funds often take more active trading positions and may invest in a wider range of assets.
• Venture Capital and Private Equity Firms: These firms invest in early-stage or private companies with high growth potential. Their investment horizons are typically longer-term, and they often play an active role in the company's management and strategic direction.

Investment Motivations:

Investors are attracted to Aligos Therapeutics, Inc. (ALGS) for a variety of reasons:

• Growth Prospects: Aligos Therapeutics, Inc. (ALGS) is a biotechnology company focused on developing novel therapies for liver diseases. Investors may be drawn to the company's potential for significant growth if its drug candidates are successful in clinical trials and receive regulatory approval.
• Market Position: The company's focus on liver diseases, an area with significant unmet medical needs, positions it favorably in a growing market. This strategic focus can be appealing to investors looking for companies with a clear market opportunity.

Investment Strategies:

The investment strategies employed by Aligos Therapeutics, Inc. (ALGS) investors vary depending on their investment goals and risk tolerance:

• Long-Term Holding: Some investors, particularly institutional investors and venture capital firms, may adopt a long-term holding strategy. This involves holding shares for an extended period, often several years, to benefit from the company's long-term growth potential.
• Short-Term Trading: Other investors, such as hedge funds and some retail investors, may engage in short-term trading strategies. This involves buying and selling shares more frequently to capitalize on short-term price fluctuations.
• Value Investing: Value investors seek to identify undervalued companies with strong fundamentals. They may invest in Aligos Therapeutics, Inc. (ALGS) if they believe the company's stock price is below its intrinsic value.

For additional insights into the financial health of Aligos Therapeutics, Inc. (ALGS), consider exploring this resource: Breaking Down Aligos Therapeutics, Inc. (ALGS) Financial Health: Key Insights for Investors

Aligos Therapeutics, Inc. (ALGS) Institutional Ownership and Major Shareholders of Aligos Therapeutics, Inc. (ALGS)

Institutional ownership in Aligos Therapeutics, Inc. (ALGS) can significantly influence its stock price and overall strategy. These large investors often have substantial resources and expertise, and their decisions can impact market sentiment and company policies.

Here's an overview of Aligos Therapeutics, Inc. (ALGS)'s top institutional investors and their recent activity:

• Top Institutional Investors: Identifying the major institutional holders provides insight into who has the most influence on the company.
• Ownership Changes: Observing whether these institutions are increasing or decreasing their positions can indicate their confidence in Aligos Therapeutics, Inc. (ALGS)'s future prospects.
• Impact on Stock: Understanding the role these investors play helps in assessing potential stock volatility and long-term stability.

As of the latest available data, the following firms are among the top institutional holders of Aligos Therapeutics, Inc. (ALGS):

Please note that precise shareholding data can fluctuate frequently. For the most up-to-date details, refer to financial data providers.

Institutional investors play a crucial role in Aligos Therapeutics, Inc. (ALGS)'s stock performance. Their investment decisions often reflect in-depth analysis and long-term outlooks, influencing both market perception and the company's strategic direction. Monitoring these investors can provide valuable insights into the potential future of Aligos Therapeutics, Inc. (ALGS).

For more information on Aligos Therapeutics, Inc. (ALGS), explore: Aligos Therapeutics, Inc. (ALGS): History, Ownership, Mission, How It Works & Makes Money

Aligos Therapeutics, Inc. (ALGS) Key Investors and Their Impact on Aligos Therapeutics, Inc. (ALGS)

Understanding the investor profile of Aligos Therapeutics, Inc. (ALGS) is crucial for gauging market sentiment and potential stock performance. Key investors can significantly influence company decisions and stock movements through their holdings and strategic actions.

While specific, real-time major investor updates and their direct influence on Aligos Therapeutics, Inc. (ALGS) as of today's date are best sourced from up-to-the-minute financial news outlets and SEC filings, we can explore the general landscape of what kind of investors are typically interested in biotech companies like Aligos, and how they might exert influence.

Here are the types of investors who might be interested in Aligos Therapeutics, Inc. (ALGS):

• Hedge Funds: These funds often seek short- to medium-term gains, and their investment decisions are driven by rigorous analysis of potential catalysts, such as clinical trial results or regulatory milestones.
• Venture Capital Firms: Venture capital firms, particularly those specializing in biotechnology, may have been early investors in Aligos, providing crucial funding during its initial stages. These firms typically have a long-term investment horizon and actively support the company's growth.
• Institutional Investors: Mutual funds, pension funds, and other large institutional investors often hold significant stakes in biotech companies. Their investment decisions are based on in-depth research and analysis, and their actions can have a substantial impact on stock prices.
• Activist Investors: While not always present, activist investors may take positions in biotech companies they believe are undervalued or have the potential for improvement. They may push for changes in management, strategy, or capital allocation to unlock value.

Investors impact Aligos Therapeutics, Inc. (ALGS) in several ways:

• Stock movements: Large purchases or sales of shares by major investors can create significant price volatility.
• Company decisions: Major investors can exert influence on company decisions through their voting rights and engagement with management.
• Market sentiment: The presence of well-known and respected investors can boost market confidence in a company.

For detailed insights into Aligos Therapeutics, Inc. (ALGS)'s financial well-being, explore Breaking Down Aligos Therapeutics, Inc. (ALGS) Financial Health: Key Insights for Investors.

Aligos Therapeutics, Inc. (ALGS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Aligos Therapeutics, Inc. (ALGS). This analysis includes major shareholders' perspectives, recent market behaviors, and analyst insights to provide a comprehensive overview.

Investor Sentiment:

Based on recent data, institutional ownership in Aligos Therapeutics, Inc. (ALGS) accounts for 30.87% of the total shares outstanding, excluding 13D/G filings. This translates to 1,640,579 shares held by institutional owners. However, there has been a decrease of -0.07 million shares, representing a -3.92% change in the most recent quarter. The fund sentiment score, which gauges how much funds are buying the stock, uses various factors to identify companies with high levels of institutional accumulation.

Major shareholders include:

• Adage Capital Partners Gp, L.l.c.
• EcoR1 Capital, LLC
• Deep Track Capital, LP
• Vivo Capital, LLC
• Vanguard Group Inc
• Baker Bros. Advisors Lp
• Hillhouse Capital Advisors, Ltd
• Trexquant Investment LP
• Ikarian Capital, LLC
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares

Recent data from INDmoney indicates that Indian investors' search interest in Aligos Therapeutics stock has increased by 11% in the last 30 days, showing a recent upward trend in interest.

Recent Market Reactions:

The stock market has reacted notably to changes in Aligos Therapeutics, Inc.'s ownership and performance. As of April 15, 2025, the share price was $4.72. Previously, on April 16, 2024, the share price was $20.88, marking a significant decline of 77.39% over that period.

Key statistics as of April 18, 2025, include:

• Today's Low: $4.42
• Today's High: $4.79
• 52 Week Low: $3.76
• 52 Week High: $46.80
• Market Capitalization: $28.6 million

The stock price experienced volatility, with a 7.92% fluctuation on April 17, 2025, moving from a low of $4.42 to a high of $4.77. The stock demonstrated mixed signals, holding a buy signal from the short-term Moving Average, but a sell signal from the long-term average.

Aligos Therapeutics, Inc. (ALGS) has a total shareholder equity of $-29.0 million and total debt of $0.0, resulting in a debt-to-equity ratio of 0%. The company's total assets are $70.1 million, while total liabilities amount to $99.1 million.

Analyst Perspectives:

Analysts following Aligos Therapeutics, Inc. provide varied insights. H.C. Wainwright reaffirmed a Buy rating with a $75.00 price target in September 2024 after positive Phase 2a HERALD study results were announced. This study demonstrated statistically significant liver fat reductions compared to a placebo for ALG-055009.

However, recent earnings reports have presented challenges. Aligos Therapeutics, Inc. reported a quarterly loss of $3.41 per share, compared to an estimated loss of $1.91. Revenues for the quarter ended December 2024 were $0.63 million, falling short of the $2.68 million from the previous year.

Based on 8 Wall Street analysts, the consensus is:

• 75% Buy
• 25% Hold
• 0% Sell

Analysts such as Ed Arce from HC Wainwright, Michael Yee from Jefferies, and Yasmeen Rahimi from Piper Sandler are actively covering Aligos Therapeutics.

For additional insights into Aligos Therapeutics, Inc., you can explore its history, mission, ownership structure, and how it operates and generates revenue: Aligos Therapeutics, Inc. (ALGS): History, Ownership, Mission, How It Works & Makes Money